GSK3326595
-
- Applikation
- Inhibition (Inh)
- Verwendungszweck
- Selective PRMT5 inhibitor
- Produktmerkmale
- GSK3326595 is a potent (IC50 = 6.2nM), selective (>4000-fold over 20 other methyltransferases), SAM uncompetitive, peptide competitive inhibitor of PRMT5. PRMT5 inhibition activated the p53 pathway via induction of alternative splicing of MDM4 leading to a potent anti-proliferative response both in vitro and in vivo. Combination therapy with palbociclib (CDK4/6 inhibitor) and GSK3326595 lead to increased efficacy of palbociclib in treating native and resistant models of melanoma via regulation of the PRMT5-MDM4 axis. Currently in clinical Trials.
- Reinheit
- >98 %
- Chemical Name
- 6-[(1-Acetylpiperidine-4-yl)amino]-N-[(2S)-3-(3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxypropyl]pyrimidine-4-carboxamide
- Formel
- C24H32N6O3
- Löslichkeit
- Soluble in DMSO (up to 20 mg/ml)
-
-
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Powder
- Lagerung
- -20 °C
-
- Hintergrund
- EPZ015938,Proliferation,Epigenetics,Posttranslational modification,Protein methyltransferase,RNA,Cancer,Chromatin,p53
- Molekulargewicht
- 452.56
- CAS-Nummer
- 1616392-22-3
-